What Is Nanobiotix S.A. (NBTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Nanobiotix S.A.'s intrinsic value is estimated at $16.47. Trading at its current price of $39.96, the valuation engine raises significant caution: 6 of 7 models flag downside risk, projecting an average implied return of -58.8%. Notably, Sentiment SOTP sees the most upside at +4.3% (fair value: $41.66), while First Chicago is the most conservative at -98.9% ($0.45). The spread between these extremes — +103.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About NBTX?
7 of 13 models are currently active for NBTX. Of these, 1 model suggests upside while 6 models suggest overvaluation. The Bayesian DCF estimates NBTX's intrinsic value at $8.42, implying -78.9% downside from the current price. See which stocks rank higher →
How Does NBTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, NBTX ranks #378 by Quality of Company score. CirclFi's QOC score of 3.4/10 evaluates 32 fundamental signals. A score of 3.4 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Nanobiotix S.A.'s positioning within the Pharmaceutical Preparations segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.
Is NBTX a Value Trap?
CirclFi's Value Trap algorithm assigns NBTX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Nanobiotix S.A.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Nanobiotix S.A. earns a quality score of 3.4/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +103.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every NBTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across NBTX's 7 active models, average confidence is 14%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad